Phase II Efficacy Study of Aerosolized Recombinant Human IL-4 Receptor in Asthma
NCT00001909
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
40
Enrollment
NIH
Sponsor class
Conditions
Asthma
Hypersensitivity
Interventions
DRUG:
Soluble recombinantly produced IL-4R
Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)